Updated:
Bioching Capital
Bioching Capital invests in early-stage medical-device and pharmaceutical companies in China.
Bioching Capital
Bioching Capital was established to back healthcare entrepreneurs operating in China. Its team draws prior operating experience at Mindray Medical and Lepu Medical. The firm commits capital across medical devices, in vitro diagnostics, pharmaceuticals, and medical services. Deployment splits 40 percent to seed and angel rounds and 60 percent to Series A and B. All activity remains inside Asia. Confirmed positions and co-investors are not publicly itemized. The firm manages approximately 1 billion RMB. No dated operational events from the last 24 months appear in available records.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shenzhen
Corporate office
Shenzhen, China
Sector focus
Frequently asked questions
What stages does Bioching Capital target?
The firm allocates 40 percent of capital to seed and angel rounds and 60 percent to Series A and B.
Which sectors receive the largest share of Bioching Capital commitments?
Medical devices account for 60 percent of the portfolio; pharmaceuticals and medical services account for the remaining 40 percent.
Where does Bioching Capital invest geographically?
All documented activity occurs inside China.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: